Home > Insider Trading > Filing (0001062993-23-018019)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1621443	Zynerba Pharmaceuticals Inc.	ZYNE	Pharmaceutical Preparations (2834)	260389433

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1988882	T Kenneth Jones	C/O Zynerba Pharmaceuticals, Inc. 80 W. Lancaster Avenue, Suite 300 Devon PA 19333	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-09-12	9,000	$0.00	88,025	No	4	A	Direct
Common Stock	Disposition	2023-09-13	2,505	$1.33	85,520	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Footnotes

On September 12, 2023, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 9,000 performance-based restricted stock awards granted in a prior year.
This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.